Close Menu

NEW YORK – Belgian molecular diagnostics firm Biocartis reported on Thursday that its full-year 2019 revenues rose nearly 35 percent year over year, driven by a global adoption of its Idylla instrument and cartridges.

Biocartis also said that it has partnered with Bristol-Myers Squibb to register its Idylla MSI test as a companion diagnostic in China.

For the 12 months ended Dec. 31, 2019, Biocartis' revenues jumped to €37.4 million ($41.9 million) from €27.8 million in 2018.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.